Mebendazole Compared with Secnidazole in the Treatment of Adult Giardiasis: A Randomised, No-Inferiority, Open Clinical Trial. (20th November 2011)

• Record Type: Journal Article
• Authors: Almirall, Pedro; Escobedo, Angel A.; Ayala, Idalia; Alfonso, Maydel; Salazar, Yohana; Cañete, Roberto; Cimerman, Sergio; Galloso, Martha; Olivero, Ilmaems; Robaina, Maytee; Tornés, Karen
• Other Names: Lindsay D. S. Academic Editor.
• Is Part Of: Journal of parasitology research. Volume 2011(2011)
• Publication Date: 2011-11-20
• Subjects: Parasitology -- Periodicals; Parasitology -- Research -- Periodicals; Parasitic Diseases; Parasitology; Parasitology; Parasitology -- Research; Electronic journals; Periodicals; Periodicals; 616.96
• DOI: 10.1155/2011/636857
• Languages: English
• ISSNs: 2090-0023

Abstract

Abstract : To compare the efficacy and safety of mebendazole and secnidazole in the treatment of giardiasis in adult patients, a single-centre, parallel group, open-label, randomized non-inferiority trial was carried out. One-hundred and 26 participants who had symptomatic Giardia mono-infection took part in the study. Direct wet mount and/or Ritchie concentration techniques and physical examinations were conducted at the time of enrolment and at the follow-up visit. The primary outcome measure was parasitological cure, performed at 3, 5, 10 days post-treatment. Negative faecal specimens for Giardia were ensured by the same parasitological techniques. At follow up (day 10) the parasitological cure rate for the per protocol populations was 88.7% (55/62) for MBZ and 91.8% (56/61) for SNZ. For the intention to treat populations the cure rate at the end of treatment was 85.9% (55/64) for MBZ and 90.3% (56/62) for SNZ. Both analyzes showed there was not significant statistical difference between MBZ and SNZ treatment efficacy. Both drugs were well tolerated, only mild, transient and self-limited side effects were reported and did not require discontinuation of treatment. A 3-day course of mebendazole seems to be as efficacious and safe for treatment of giardiasis as a single dose of secnidazole in adults.